Siludi Pharmaceutical Co., Ltd. (01244): Envida® has been certified as an orphan drug for gastric cancer and gastroesophageal junction cancer indications

Zhitong Finance App News, Siludi Pharmaceutical Co., Ltd. (01244) announced that its commercial product Enveda® (generic name: Envolizumab injection, original research code: KN035) has been officially certified as an orphan drug for gastric cancer and gastroesophageal junction cancer indications. This is the third orphan drug indication successfully approved by Enveda® after being indicated for cholangiocarcinoma and soft tissue sarcoma.

The phase II clinical study approved for advanced gastroesophagastric adenocarcinoma based on Envida® carried out by the company showed clear anti-tumor efficacy. The objective response rate in combination with FOLFOX was 60%, the disease control rate was as high as 100%, and the safety and tolerability were good, and there were no adverse events leading to termination of treatment or death.